Stock Analiz

Lite Strategy, Inc. LITS

Biotechnology: Pharmaceutical Preparations · IPO 2003 · data as of November 13, 2026

$0.85Market cap $25M
Open the interactive analysis →

Lite Strategy, Inc. (LITS) is a healthcare company listed in the US with a market value of about $25M. In fiscal year 2026 it had revenue of $267000 and net income of -$71M, a net margin of -26647.9%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -62% a year, a 5-year average ROIC of -88%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Lite Strategy

Lite Strategy is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2003. Revenue went from $23M in 2017 to $267000 in 2026, a decline of about 39.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 419% over three years (dilution for shareholders). It spends 46% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S94.8
P/B0.4
EV/EBITDA—
PEG—
Dividend yield—
FCF yield—
Shareholder yield19.4%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-62.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-6704.6%
ROIC (5-yr avg.)-87.8%
Profitable years (of last 10)2
Years paying a dividend1

Financials, last 10 years

Fiscal year2026202520242023202220212020201920182017
Revenue$267000$0$65M$49M$41M$35M$28M$5M$2M$23M
Net income-$71M-$16M$18M-$32M-$54M-$41M-$47M-$17M-$40M$3M
Free cash flow—-$21M-$50M-$53M-$49M-$33M$33M-$30M—$3M
EPS (diluted)$-2.06$-2.39$2.67$-4.78$-9.99$-12.00$-10.40$-15.00$-19.40$1.40
Net margin-26647.9%—27.6%-65.5%-132.7%-117.8%-170.0%-342.2%-2470.3%11.5%
ROIC-159.9%-103.1%44.0%-98.4%-121.6%-82.6%-26.3%-76.2%-44.8%4.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Lite Strategy stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Lite Strategy pay a dividend?

Not currently.

Is Lite Strategy a good stock to buy?

We do not give buy or sell advice. Lite Strategy scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.